Manuel
Barreiro de Acosta
Instituto de Investigación Sanitaria del Hospital Universitario La Paz
Madrid, EspañaPublicacións en colaboración con investigadores/as de Instituto de Investigación Sanitaria del Hospital Universitario La Paz (16)
2024
-
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588
-
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease
Gastroenterologia y Hepatologia
-
Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients
Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182
-
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis
Gastroenterologia y Hepatologia, Vol. 47, Núm. 5, pp. 522-552
2023
-
Current management of bowel failure due to Crohn's disease in Spain: Results of a GETECCU survey
Gastroenterologia y Hepatologia, Vol. 46, Núm. 6, pp. 439-445
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review
Advances in Therapy, Vol. 40, Núm. 5, pp. 1975-2014
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
-
Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort
Scandinavian Journal of Gastroenterology
-
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Vol. 55, Núm. 1, pp. 46-52
2022
-
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Biomedicines, Vol. 10, Núm. 3
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection
Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 668-676
-
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study
Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2020
-
Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey
Inflammatory bowel diseases, Vol. 26, Núm. 8, pp. 1149-1154